Ask which of these two is "stronger" and you will get an answer built from two percentages lifted out of two unrelated trials. It is the wrong comparison, made confidently, and it obscures the one difference that actually distinguishes the molecules.
The difference that is real
Tirzepatide activates two receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor1. Retatrutide activates those two and adds a third, the glucagon receptor2.
The architectural difference, before any efficacy number enters the conversation
Tirzepatide, dual
- GIP receptor
- GLP-1 receptor
- Acts mainly on insulin secretion and appetite
Retatrutide, triple
- GIP receptor
- GLP-1 receptor
- Glucagon receptor, the addition
- The glucagon arm adds energy expenditure and hepatic effects
That third arm is not more of the same. GLP-1 and GIP agonism act largely on insulin secretion, gastric emptying and appetite. Glucagon receptor agonism pulls a different lever: energy expenditure and hepatic metabolism.
It also sounds paradoxical, because glucagon raises blood glucose, which is exactly what a diabetes drug is supposed to avoid. The design bet is that the incretin arms more than offset that effect while the glucagon arm contributes on the energy side. Whether that bet holds across a full phase 3 programme is, at the time of writing, not settled.
We take each compound apart separately in what the retatrutide trials show and the tirzepatide record.
Why the percentages cannot be subtracted
Here is the part that gets skipped.
Four reasons a number from one trial cannot be subtracted from a number in another
- Different people
- Entry criteria, baseline weight and comorbidities differ between programmes, and baseline drives how much can be lost.
- Different duration
- 72 weeks and 48 weeks do not produce comparable endpoints; these curves had not plateaued.
- Different endpoint
- Least-squares mean change, treatment-regimen estimand, completer analysis, the same trial yields different figures under each.
- Different phase
- A phase 2 dose-finding population is selected differently from a phase 3 population, and phase 2 results usually shrink.
Placing "−24.2% at 48 weeks" beside "−20.9% at 72 weeks" and concluding one is better is not a comparison, it is two facts printed next to each other. The populations were selected differently, the durations differ, the estimands differ, and one programme is a phase 2 dose-finding study while the other is a completed phase 3.
The only comparison that would settle the question is a head-to-head trial: same protocol, same population, randomised between the two. That is how tirzepatide was compared with semaglutide, and it is why that particular comparison carries weight while cross-trial arithmetic does not.
No such trial exists for these two.
Evidence weight is not symmetrical
This is the asymmetry most write-ups flatten.
Tirzepatide has completed phase 3 programmes in diabetes and obesity, has been through regulatory review, and has a safety database of the size that process requires. Retatrutide's obesity evidence is a phase 2 trial2, real, well-conducted, and a stage earlier.
Phase 2 results systematically look better than what phase 3 confirms. Not because anyone is cheating: dose-finding studies are smaller, populations are more selected, and the effects that get published are the ones that cleared a bar. Expecting some regression is the correct prior, not cynicism.
So the honest ranking is not "retatrutide beats tirzepatide". It is: one has been tested more, and the other has a mechanistic argument for why it might do more, which has not yet been through the test that would confirm it.
What differs in the vial, very little
For laboratory handling, the pharmacological distance between these two shrinks to almost nothing.
Both are 39-residue synthetic peptides with fatty-acid modification, and their molecular masses sit within about 80 g/mol of each other, 4731 against 4813. Both carry that acyl chain for the same reason, described in the fatty acid trick: to bind albumin and survive in circulation.
They dissolve similarly, degrade by the same routes in solution, and demand the same storage discipline. Nothing about triple versus dual agonism changes how you reconstitute the powder or how long the solution lasts.
How to read a comparison honestly
Three questions strip most of the noise out.
Was it head to head? If not, the comparison is inference, however confident the phrasing.
Same phase? A phase 2 number and a phase 3 number are not the same kind of claim.
Same endpoint and duration? These change the figure substantially within a single trial, let alone between two.
Applied here, they produce a duller but defensible summary. Retatrutide adds a mechanism tirzepatide does not have, and the early data are strong. Tirzepatide has been tested to a standard retatrutide has not yet reached. Both statements are true, and neither is a ranking.
